Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1989;80:128-137

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wesley, R. C.
Right arrow Articles by Belardinelli, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wesley, R. C., Jr
Right arrow Articles by Belardinelli, L.

Circulation, Vol 80, 128-137, Copyright © 1989 by American Heart Association


ARTICLES

Role of endogenous adenosine in postdefibrillation bradyarrhythmia and hemodynamic depression

RC Wesley Jr and L Belardinelli
Department of Medicine, University of Virginia Medical Center, Charlottesville.

In halothane-nitrous oxide-anesthetized pigs, the effect of the competitive adenosine antagonist, BW-A1433U (a derivative of 1,3- dipropyl-8-phenylxanthine), on postdefibrillation bradyarrhythmia and hemodynamic depression was investigated. In protocol 1, repetitive episodes of ventricular fibrillation lasting 15 seconds before transthoracic DC shock were performed in five animals, before (control) and after the administration of BW-A1433U (5 mg/kg i.v.). An unsuccessful initial shock was immediately followed by a rescue shock of 40 A. In ventricular fibrillation episodes requiring rescue shocks, nine of 19 episodes (47%) exhibited second- or third-degree atrioventricular block at 15 seconds postdefibrillation compared with only one of 16 BW-A1433U episodes (6%). In protocol 2, the effect of BW- A1433U was determined in the presence of dipyridamole, a nucleoside uptake blocker known to potentiate the cardiac actions of adenosine. To counter the hypotensive effect of dipyridamole, methoxamine was continuously infused at 0.015 mg/kg/min i.v. Sequential episodes of ventricular fibrillation lasting 45 seconds were terminated by shocks of 40 A in the presence of methoxamine alone, after dipyridamole (1.5- 7.5 mg i.v.), and after BW-A1433U (5 mg/kg i.v.). Over the first 15 seconds postdefibrillation, BW-A1433U significantly (p less than 0.05) increased the number of spontaneous beats (31 +/- 2) and systolic/diastolic blood pressure (111 +/- 4/67 +/- 5 mm Hg; mean +/- SEM; n = 9) compared with both methoxamine (16 +/- 2 beats; 98 +/- 14/52 +/- 12 mm Hg; n = 5) and dipyridamole (8 +/- 3 beats; 58 +/- 11/27 +/- 6 mm Hg; n = 9), respectively. Rapid infusion of BW-A1433U during dipyridamole postdefibrillation periods raised heart rate and blood pressure to preventricular fibrillation levels within 30 seconds. Thus, BW-A1433U can reverse and prevent postdefibrillation bradyarrhythmia and hemodynamic depression. Endogenous adenosine may be an important mediator of postdefibrillation cardiovascular collapse.


This article has been cited by other articles:


Home page
CirculationHome page
A. Zaza, M. Rocchetti, and D. DiFrancesco
Modulation of the Hyperpolarization-Activated Current (If) by Adenosine in Rabbit Sinoatrial Myocytes
Circulation, August 15, 1996; 94(4): 734 - 741.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
B. D. Bertolet, E. B. McMurtrie, J. A. Hill, and L. Belardinelli
Theophylline for the Treatment of Atrioventricular Block after Myocardial Infarction
Ann Intern Med, October 1, 1995; 123(7): 509 - 511.
[Abstract] [Full Text]


Home page
CirculationHome page
B. B. Lerman and E. D. Engelstein
Metabolic Determinants of Defibrillation : Role of Adenosine
Circulation, February 1, 1995; 91(3): 838 - 844.
[Abstract] [Full Text]